Guardant Health (FRA:5GH) Additional Paid-In Capital : €2,143.5 Mil(As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Guardant Health Additional Paid-In Capital?

Guardant Health's quarterly additional paid-in capital increased from Sep. 2023 (€2,050.9 Mil) to Dec. 2023 (€2,113.0 Mil) and increased from Dec. 2023 (€2,113.0 Mil) to Mar. 2024 (€2,143.5 Mil).

Guardant Health's annual additional paid-in capital increased from Dec. 2021 (€1,467.0 Mil) to Dec. 2022 (€1,644.6 Mil) and increased from Dec. 2022 (€1,644.6 Mil) to Dec. 2023 (€2,113.0 Mil).

Guardant Health Additional Paid-In Capital Historical Data

The historical data trend for Guardant Health's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Guardant Health Additional Paid-In Capital Chart

Guardant Health Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Additional Paid-In Capital

Get a 7-Day Free Trial

1,035.08

1,563.76

1,466.97

1,644.56

2,112.97

Guardant Health Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Additional Paid-In Capital	Get a 7-Day Free Trial															1,647.15	2,002.83	2,050.90	2,112.97	2,143.54

Guardant Health Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Guardant Health Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Guardant Health's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Guardant Health (FRA:5GH) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Guardant Health Inc (FRA:5GH) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

GH:USA

Address

3100 Hanover Street, Palo Alto, CA, USA, 94304

Website

https://www.guardanthealth.com

Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.

Guardant Health (FRA:5GH) Headlines

No Headlines